Limited information is available about the transfer of articaine into breast milk and the associated risks to breastfed infants.
Prediction of Clinical Outcomes in a Heterogenous NSCLC Virtual Patient Population: a Quantitative Systems Pharmacology (QSP) Approach
Non-small cell lung cancer (NSCLC) is a major cause of mortality in the United States[1].
Quantitative Systems Toxicology (QST) Modeling Using BIOLOGXsym and Mechanistic Toxicity Data From a Biomimetic Liver Microphysiology System Predicts Biologics-induced Liver Injury
While biologics offer promise in addressing a range of unmet medical needs, clinically observed BILI events are concerning for drug developers, health care providers and patients.
Using Model Master Files to Support Oral Drug Product Development and Regulatory Submissions
This report summarizes the proceedings of Session 2 of the two-day public workshop titled “Considerations and Potential Regulatory Applications for a Model Master File” hosted by the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) on May 2–3, 2024.
ADMET Predictor® 13: Predict & Build with Confidence
ADMET Predictor 13 is almost here—and in this webinar, you’ll see how it gives your organization the First-to-Invent Advantage! Drs. David Miller, Vice President, ADMET Cheminformatics, and Michael Lawless, Sr. Principal Scientist, Cheminformatics Solutions walk you through the latest version of the software...
Nitrosamines Risk Assessment for Biopharmaceutics Classification System Class IV Molecule Containing Immediate Release Products: Use of In-Silico Prediction Tools and Physiologically Based Pharmacokinetic Modeling
Nitrosamines drug substance related impurities (NDSRI) are organic impurities, highly potent mutagenic substances that are classified as human carcinogens.
Predicting Brinzolamide Ocular Response in Humans Using an Ocular PBPK-PD Modeling and Simulation
The development of generic ophthalmic drug products indicated for intraocular pressure (IOP) reduction typically relies on comparative pharmacodynamic (PD) endpoint bioequivalence (BE) studies.
Intestinal Secretion Is a Potentially Important Clearance Mechanism for Low Metabolic Clearance Compounds
Intestinal excretion/secretion (IE) from the systemic circulation via the enterocytes into the intestinal lumen has traditionally been considered a minor clearance (CL) pathway.
Framework for Classifying Chemicals for Repeat Dose Toxicity Using NAMs
EPAA’s ‘NAM Designathon 2023’ challenge for human toxicity sought to identify a classification system capable of categorising chemicals based on their bioactivity and bioavailability properties determined using non-animal methodologies (Worth et al. 2025).
Multi-target Property Prediction and Optimization Using Latent Spaces of Generative Model
Multi-target property prediction has the potential to improve generalization by exploiting the positive transfer between targets.
Investigation of the Suitability of Utilizing Plasma Concentration as a Surrogate to Understand Lung Exposure of Inhaled Drug in Rats: Different Delivery Methods of Fluticasone Propionate
Pulmonary diseases, such as asthma and chronic obstructive pulmonary disease (COPD) are complex human airway diseases that affect millions of people worldwide.
From Lab-to-Clinic with Model Informed Formulation Development: a Case Study of Hydroxyzine SR Tablets
Model Informed Formulation Development (MIFD) uses physiologically based pharmacokinetic (PBPK) modelling and other in silico tools to facilitate new product development.
Beyond the Lab: FDA’s Vision for Modeling a Future Without Animal Testing
The FDA has released a new roadmap outlining a path toward reducing—and ultimately replacing—animal studies in pharmaceutical development with new approach methodologies (NAMs), beginning with monoclonal antibodies.
Accessing DDI Standards in the Simulations Plus Training Portal
Your GastroPlus DDI Module license grants you access to our DDI reports and databases through the Simulations Plus Training Portal. You must register on the portal with your company email address in order to access these resources.
Simulations Plus Releases DILIsym® 11
Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations
Quantitative Systems Toxicology Modeling of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended-Release and Immediate-Release Formulations in Adults With Chronic Alcohol Use or Low Glutathione
Acetaminophen (APAP), an over-the-counter analgesic and antipyretic, can cause hepatotoxicity when ingested in large overdoses.
Drug-Induced Liver Injury: A Look at QST Modeling and AI Predictions
As AI tools gain traction in drug development, there is growing enthusiasm around their potential to predict drug-induced liver injury (DILI).
Beyond the Linear Model in Concentration-QT Analysis
This work introduces several extensions for concentration-QT modeling in a pharmacometric context.
Smarter Clinical Development: How to Use QSP to Maximize the Value of GLP-1 Agonists
As the market for GLP-1 agonists expands, biotech companies face both immense opportunity and fierce competition. To stand out in this evolving landscape and enhance the likelihood of acquisition or out-licensing, early-stage companies must develop a strategic, data-driven clinical development plan.
A Well-Characterized Mechanistic Model for Exploring Known or Hypothesized T cell Mediated Drug Induced Liver Injury: Current Capabilities and Challenges for Future Predictivity
Drug-induced liver injury (DILI) is an adverse event whose emergence can slow or halt drug development programs.